In particular, three genes (PLAU, MMP-1, and LGALS3)—besides LCN2, whose role in aggressive thyroid cancer has been discussed above—are highly sensitive to NF-κB inhibition in BRAFV600E-mutated PTC cells [50]. This evidence concerns the gene LCN2 and thyroid gland carcinoma.